Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
JM Banales, JJG Marin, A Lamarca… - Nature reviews …, 2020 - nature.com
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
超声内镜在胆管癌诊治中的应用进展.
宋红召， 李彤彤， 李喆楠… - Journal of Clinical …, 2024 - search.ebscohost.com
通信地址: 吉林省长春市朝阳区新疆街461 号吉林大学白求恩第一医院转化医学研究院医学出版
中心邮政编码: 130061 电话号码: 0431-88782044/3542 电子信箱: lcgdb@ vip. 163. com …
中心邮政编码: 130061 电话号码: 0431-88782044/3542 电子信箱: lcgdb@ vip. 163. com …
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single …
DY Oh, KH Lee, DW Lee, J Yoon, TY Kim… - The Lancet …, 2022 - thelancet.com
Background Immunotherapies have shown clinical activity in patients with advanced biliary
tract cancer, for which outcomes remain poor despite standard of care treatment with …
tract cancer, for which outcomes remain poor despite standard of care treatment with …
Molecular targeted therapies: ready for “prime time” in biliary tract cancer
A Lamarca, J Barriuso, MG McNamara, JW Valle - Journal of hepatology, 2020 - Elsevier
The prognosis for patients with biliary tract cancers (cholangiocarcinoma and gallbladder
cancer) is poor, while the incidence of these cancers is increasing. Most patients are …
cancer) is poor, while the incidence of these cancers is increasing. Most patients are …
Recent advances of immunotherapy for biliary tract cancer
A Rizzo, AD Ricci, G Brandi - Expert review of gastroenterology & …, 2021 - Taylor & Francis
Introduction: Biliary tract cancer (BTC) is a heterogeneous group of aggressive malignancies
comprising intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder …
comprising intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder …
[HTML][HTML] How I treat biliary tract cancer
Highlights•Surgical resection remains the mainstay of cure for BTC.•Adjuvant therapy for 6
months with capecitabine is recommended after surgery.•Palliative treatment: CisGem …
months with capecitabine is recommended after surgery.•Palliative treatment: CisGem …
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
A Rizzo, AD Ricci, G Brandi - Expert opinion on investigational …, 2021 - Taylor & Francis
Introduction: The prognosis of patients with advanced biliary tract cancer (BTC) remains
dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint …
dismal, with a 5-year overall survival rate of less than 10%. Although immune checkpoint …
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives
A Rizzo, AD Ricci, G Brandi - Expert Opinion on Investigational …, 2021 - Taylor & Francis
ABSTRACT Introduction Biliary tract cancers (BTCs) are poor prognosis malignancies
usually classified in intrahepatic cholangiocarcinoma (iCCA), extrahepatic …
usually classified in intrahepatic cholangiocarcinoma (iCCA), extrahepatic …
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
RIR Macias, V Cardinale, TJ Kendall, MA Avila… - Gut, 2022 - gut.bmj.com
Cholangiocarcinoma (CCA) is a malignant tumour arising from the biliary system. In Europe,
this tumour frequently presents as a sporadic cancer in patients without defined risk factors …
this tumour frequently presents as a sporadic cancer in patients without defined risk factors …